Bisoprolol (Concor)
What studies of Bisoprolol (Concor) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Bisoprolol (Concor) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Bisoprolol (Concor) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Autonomic symptoms1 study · 1 (few people) person took Bisoprolol (Concor) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 2.5 mg, daily (few people)
Autonomic symptoms improved.
The evidence is very uncertain about the effect of bisoprolol (Concor) on autonomic symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (2021)
- People in the study
- 1 in the study
- Dose
- 2.5 mg, daily
- Outcome
- standing heart rate
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 1 (few people) person took Bisoprolol (Concor) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 2.5 mg, daily (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of bisoprolol (Concor) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (2021)
- People in the study
- 1 in the study
- Dose
- 2.5 mg, daily
- Outcome
- symptoms
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
0.625 to 2.5 mg at the start
- 2Raise
Raised step by step in 1 of 2 studies
- 3Top dose
Most often 2.5 mg (2 of 2 studies)
Doses across 2 studies
0.625 to 2.5 mg.
Each study’s dose, as printed
- 2.5 mg, daily Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (2021)
- 0.625 to 2.5 mg, once daily Treatment of long COVID complicated by postural orthostatic tachycardia syndrome-Case series research. (2024)
All papers
- Treatment of long COVID complicated by postural orthostatic tachycardia syndrome2023 · compared with another group · 34 started · 32 with outcome data · preprint
- Post-COVID-19 Postural Orthostatic Tachycardia Syndrome2021 · case report · 1 in the study
Summary
This case report describes a 25-year-old woman who developed new-onset postural orthostatic tachycardia syndrome (POTS) after COVID-19 infection without pneumonia. The paper reports one patient. Her tilt test showed an increase in heart rate from 80 bpm in the supine position to 110 bpm without hypotension, fitting POTS criteria. She was given lowdose bisoprolol at 2.5 mg oral daily. The report does not state the treatment duration or a follow-up period. There was no comparison group; the report is a single-patient observation. The outcomes described are standing heart rate and symptoms. The authors report that lowdose bisoprolol reduced the standing heart rate and improved symptoms acutely (Picture B). No harms or side effects are reported, and the text does not report any withdrawals. The authors state that they have no conflict of interest. They do not state limitations of the report in the provided text. No numerical baseline or follow-up values for standing heart rate or symptoms are reported, only the tilt-test heart rates. No randomisation or blinding is reported.
- Endothelial Dysfunction in a Patient With Post-COVID-19 Syndrome and Mutation of the MTHFR Gene and Prothrombin II.2025 · combination: given with other treatments · 1 in the study
Summary
This case report describes a 25-year-old Mexican woman with post-COVID-19 syndrome and chest pain and dyspnea. The report is a single case presentation. One patient was enrolled, started treatment, and was analysed. No comparison group, randomisation, or crossover was reported. Treatment included short-term prophylactic apixaban with low-dose aspirin; colchicine and indomethacin were also initiated; the final treatment consisted of folic acid and vitamin B complex supplementation, low-dose aspirin, bisoprolol, and trimetazidine for angina control. Isosorbide was discontinued due to severe headache, and diltiazem yielded no significant improvement. Treatment duration was not reported; follow-up was at one year. The recorded outcomes were clinical improvement with a reduction in the frequency and intensity of angina, and a significant reduction in frequency and intensity of chest pain. The authors state that at a one-year follow-up the patient showed clinical improvement. Apixaban was discontinued after discharge. The authors acknowledge the limitation of reporting a single case.
- Treatment of long COVID complicated by postural orthostatic tachycardia syndrome-Case series research.2024 · combination: given with other treatments · 34 in the study · 32 started · 32 with outcome data
Summary
The authors aimed to describe the treatment course of long COVID complicated by POTS. At the outpatient clinic of St. Marianna University Hospital, 34 patients met POTS criteria; 32 were followed after excluding 2 who had only two visits because of hospital transfer. Median follow-up was 159 (IQR: 90.5–264.5) days. Treatment included counseling to consume ≥10 g of salt and 2–3 L of water, elastic compression stockings, and bisoprolol 0.625 to 2.5 mg once daily, with SSRIs, midodrine, rTMS, EAT, Chinese herbal medicine, or psychiatrist consultation in some cases. There was no comparison group. After 2 weeks to 1 month, 19 patients were aware of the effects of bisoprolol treatment and 13 were unaware. From initial to last visit, ΔHR improved from 38 (34–43.5) to 17.5 (13–28) and PS score from 4 (2–6) to 1 (0–2). Employment or study status “continued with the same job description or went to school” changed from 10 (31.3%) to 22 (68.8%), and “leave of absence or school leave” from 13 (40.6%) to 5 (15.6%). Harms were not reported. Authors state limitations: single-center descriptive study; patients referred from neighboring institutions.
- Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic.2024 · systematic review
Summary
This systematic review asked whether oral medications for POTS have evidence, including in PASC-associated POTS. The search was conducted through 6 April 2024 and included 32 studies of oral medications; treatment durations varied across studies. The review compared medication arms with placebo or active comparators where available and summarized symptomatic response and change in positional heart rate variability. For PASC-associated POTS, ivabradine had 78.18% treatment success versus 72.45% in pooled non-COVID studies, while a beta-blocker had 59.38% versus 65.12%. In placebo comparisons, midodrine had a treatment success ratio of 0.89 versus 0.53, metoprolol 0.58 versus 0.53, and ivabradine SF-36 physical functioning change was 11.8 versus 2.5. In active comparisons, bisoprolol and propranolol endpoints were largely similar, and adding pyridostigmine did not significantly improve symptom scores. The review reports limitations including only English-language inclusion, lack of standardized symptom scoring and treatment success definitions, unclear randomization/blinding in several RCTs, and few long-term RCTs. No worsening, withdrawal, or side-effect counts were reported in the recorded data.
- Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
Summary
This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.